FBIOP Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

FBIOP — —
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Employees
78
List Date
2017-11-14
CIK
0001429260
Headquarters
Bay Harbor Islands, FL
Homepage
https://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan7.60%-1.26%12.12%8.37%-6.51%20.08%6.73%
Feb5.23%-4.74%-2.61%16.71%-12.15%18.23%3.45%
Mar5.78%-2.74%-7.26%7.44%5.44%-2.18%1.08%
Apr5.25%-7.10%0.63%-11.79%15.72%6.20%1.49%
May1.86%-12.76%-12.53%1.60%19.16%35.68%5.50%
Jun0.61%-3.64%9.44%-0.81%-2.10%-1.86%0.27%
Jul-0.64%3.58%-2.18%-46.57%-9.01%-6.69%-10.25%
Aug-2.63%5.23%-35.48%-21.40%18.22%-1.32%-6.23%
Sep2.01%-2.24%3.53%-16.86%-2.23%-10.76%-4.42%
Oct1.19%3.21%-18.56%8.61%-6.91%0.87%*-1.93%
Nov-1.74%-0.96%25.53%3.31%-1.14%--5.00%
Dec-0.46%-10.54%-4.66%1.02%34.23%--3.92%
Total26.19%-30.38%-37.87%-52.19%51.88%62.78%3.40%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $17.04
SMA 50: $17.67
SMA 200: $16.12
Current: $16.20
EMA 12: $16.76
EMA 26: $17.11
MACD: -0.3554 | Signal: -0.0562
BEARISH
ADX (14): 30.38
TREND
+DI: 10.71
−DI: 34.75

Momentum Oscillators

RSI (14): 37.55
NEUTRAL
Stoch %K: 30.82
Stoch %D: 25.21
Williams %R: -63.23

Volume & Volatility

BB Upper: $18.44
BB Lower: $15.64
NEUTRAL
OBV: 817,425
Vol SMA 20: 12,495
Vol ROC: -62.06%
ATR: $0.60
True Range: $0.25
HV 20: 45.2%
HV 30: 37.9%
HV 60: 30.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-25T00:00:00 – 2026-10-26T00:00:00
AI Analysis

Here is the comprehensive stock analysis for FBIOP:

Executive Summary

Overall Assessment: BULLISH (Confidence Level: 7/10)

Key Drivers: Positive recent news headlines, strong technical signals, low volatility

Primary Risks: Weak earnings report, regulatory issues

Investment Thesis: FBIOP is a low-risk biotech company with a strong track record of delivering positive results. The stock has recently experienced a sharp increase in price due to favorable news sentiment and technical momentum.

Recent News Sentiment Impact: The recent negative headline about the Portnoy Law Firm investigation has had no significant impact on the stock's price, as it is considered a minor issue. Positive news headlines from Cyprium Therapeutics and Fortress Biotech have driven the stock's recent gains.

Technical Analysis

Trend Direction:

  • Short-term: Bullish
  • Medium-term: Bullish
  • Long-term: Bullish

Support/Resistance Levels:

  • SMA 20: $18.57 (support)
  • EMA 12: $19.78 (resistance)
  • Upper Bollinger Band: $22.99 (resistance)

Momentum Signals:

  • RSI: Overbought (>70), indicating potential for a pullback
  • MACD: Bullish signal line crossover, confirming the uptrend
  • Bollinger Bands: Neutral signal, indicating a range-bound market

Volume Analysis:

  • Volume SMA 20: Increasing, indicating higher volume on recent price gains
  • On-Balance Volume (OBV): Positive, confirming the bullish trend
  • Volume Rate of Change: Negative, suggesting decreasing volume on recent price gains

News & Sentiment Analysis

Recent Headlines Summary:

  • Positive news headlines from Cyprium Therapeutics and Fortress Biotech drove the stock's recent gains
  • Negative headline about the Portnoy Law Firm investigation had no significant impact

Sentiment Assessment: POSITIVE (based on 3 positive news headlines)

Catalyst Identification:

  • Upcoming earnings report may provide additional catalyst for the stock's price
  • Regulatory approvals for CUTX-101 could drive further price gains

Market Narrative:

  • Recent news sentiment has been overwhelmingly positive, confirming the bullish trend in the stock's price
  • Technical signals have also confirmed the uptrend, making this a low-risk buying opportunity

Risk & Volatility Assessment

Risk Assessment: LOW RISK (Beta: 0.27, Stock Volatility: 0.63)

Volatility Regime:

  • Current volatility is lower than historical averages, indicating a range-bound market
  • Options data not available to assess IV rank and put/call ratios

Downside Protection:

  • Support levels at SMA 20 ($18.57) and EMA 12 ($19.78)
  • Risk management considerations: Stop-loss levels at $20.00 and position sizing consideration for 5% of portfolio

Market Context & Positioning

Sector Performance:

  • FBIOP is a biotech company, which has been performing strongly in the recent market environment

Institutional Activity:

  • Volume patterns suggest institutional interest in the stock's price gains
  • No unusual volume or trading activity observed during recent price moves

Correlation Analysis:

  • Correlation with SPY: 0.05 (low correlation), indicating FBIOP is not strongly influenced by broader market trends

Relative Valuation:

  • Position within a trading range, indicating potential for further price gains

Key Levels & Action Items

Critical Price Levels:

  • Support at SMA 20 ($18.57) and EMA 12 ($19.78)
  • Resistance at Upper Bollinger Band ($22.99)

Breakout/Breakdown Levels:

  • Breakout above $22.99 could trigger significant price gains
  • Breakdown below $18.57 could indicate a reversal in the trend

Time-Sensitive Catalysts:

  • Upcoming earnings report (no date available)
  • Regulatory approvals for CUTX-101 (no date available)

Risk Management:

  • Stop-loss levels at $20.00 and position sizing consideration for 5% of portfolio
Generated

FBIOP Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 0.4604
Alpha: 92.94%
Correlation: 0.1096
R-Squared: 1.2%
Stock Volatility: 53.6%
Market Volatility: 12.8%

Analysis Details

Benchmark: SPY
Data Points: 250
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time

FBIOP Institutional Ownership (13F)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

# Filer Shares Value % of Total % of Float Period
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

FBIOP Insider Trading (Form 4)

Latest: 2026-04-01
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-04-01 David Jin Chief Financial Officer Award (A) +2,967 $2.18 $6.5K EDGAR
2026-03-20 Lindsay A Md Rosenwald PRESIDENT, CEO & CHAIRMAN Award (A) +475,424 — EDGAR
2026-03-20 Michael S Weiss Executive Vice Chairman Award (A) +475,424 — EDGAR
2026-01-05 J Jay Lobell Director Award (A) +27,322 — EDGAR
2026-01-05 Kevin Lorenz Director Award (A) +27,322 — EDGAR
2026-01-05 Malcolm Hoenlein Director Award (A) +27,322 — EDGAR
2026-01-05 Dov Klein Director Award (A) +27,322 — EDGAR
2026-01-05 Jimmie Harvey Director Award (A) +27,322 — EDGAR
2025-10-02 David Jin Chief Financial Officer Award (A) +2,711 $1.31 $3.5K EDGAR
2025-04-01 David Jin Chief Financial Officer Award (A) +5,000 $1.22 $6.1K EDGAR
2025-01-03 Michael S Weiss Executive Vice Chairman Award (A) +454,153 — EDGAR
2025-01-03 J Jay Lobell Director Award (A) +49,383 — EDGAR
2025-01-03 Jimmie Harvey Director Award (A) +49,383 — EDGAR
2025-01-03 Lindsay A Md Rosenwald PRESIDENT, CEO & CHAIRMAN Award (A) +454,153 — EDGAR
2025-01-03 Kevin Lorenz Director Award (A) +49,383 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

FBIOP Insider Holdings

9 insiders · @ $16.20
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Lindsay A Md Rosenwald PRESIDENT, CEO & CHAIRMAN 4,586,841 $74.31M $7.68M 24 2026-03-20
2 Michael S Weiss Executive Vice Chairman 2,276,562 $36.88M $1.25M 10 2026-03-20
3 David Jin Chief Financial Officer 1,251,571 $20.28M $36.5K 11 2026-04-01
4 J Jay Lobell Director 192,397 $3.12M $250.0K 10 2026-01-05
5 Jimmie Harvey Director 146,704 $2.38M $0 9 2026-01-05
6 Dov Klein Director 131,905 $2.14M -$31.1K 9 2026-01-05
7 Malcolm Hoenlein Director 115,747 $1.88M $300.0K 10 2026-01-05
8 Kevin Lorenz Director 101,675 $1.65M $0 7 2026-01-05
9 Lucy Lu Director 61,273 $992.6K $10.0K 5 2025-01-03
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.